Is Erasca (ERAS) Quietly Reframing Its RAS Strategy With Tango's Dual-Target Trial Collaboration? [Yahoo! Finance]
Erasca, Inc. (ERAS)
Company Research
Source: Yahoo! Finance
glue ERAS-0015 with Tango's PRMT5 inhibitor vopimetostat in MTAP-deleted pancreatic and RAS-mutant non-small cell lung cancer. The combination seeks to exploit the dependency created by co-occurring MTAP deletions and RAS mutations, aiming for a dual-targeted approach that could more effectively shut down RAS signaling and PRMT5 activity in these difficult-to-treat tumors. We will now examine how this dual-targeted RAS and PRMT5 combination approach could influence Erasca's investment narrative and long-term positioning. Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource. What Is Erasca's Investment Narrative? To own Erasca today, you really have to believe that its RAS-focused platform can turn early science into clinically meaning
Show less
Read more
Impact Snapshot
Event Time:
ERAS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ERAS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ERAS alerts
High impacting Erasca, Inc. news events
Weekly update
A roundup of the hottest topics
ERAS
News
- Erasca CMO's Direct Stake Hit Zero. Her Options Position Didn't [Yahoo! Finance]Yahoo! Finance
- Assessing Erasca (ERAS) Valuation After ERAS-0015 Licensing Win And Data Anticipation [Yahoo! Finance]Yahoo! Finance
- Erasca (ERAS) Adds 13%; Soars 310% YTD [Yahoo! Finance]Yahoo! Finance
- Erasca (ERAS) had its price target raised by JPMorgan Chase & Co. from $24.00 to $25.00. They now have an "overweight" rating on the stock.MarketBeat
- Erasca (ERAS) had its price target raised by Guggenheim from $12.00 to $20.00. They now have a "buy" rating on the stock.MarketBeat
ERAS
Earnings
- 11/12/25 - In-Line
ERAS
Sec Filings
- 3/16/26 - Form 144
- 3/12/26 - Form 10-K
- 3/12/26 - Form 8-K
- ERAS's page on the SEC website